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Abstract 
Background: Discussion of Low Carbohydrate Diet (LCD) and Calorie Restriction (CR) has been observed. Authors have 
continued clinical research on LCD, CR and Morbus (M) value for years.  
 
Subjects and Methods: Subjects were 81 female patients with type 2 diabetes mellitus (T2DM). Methods included i) basal tests 
on diabetes, ii) daily profile of blood glucose, average glucose, M value for CR meal, iii) same exam of ii) for 2 days of LCD, iv) 
Triglyceride check for 12 days of LCD, v) analyses of these biomarkers.  
 
Results: Obtained data were as follows: average age 62.4 years old, median values are HbA1c 7.2%, fasting glucose 147 mg/dL, 
IRI 6.8 μU/mL, HOMA-R 2.5, HOMA-β 28.7, respectively. Median values on day 2 vs 14: average glucose 173 vs 130 mg/dL, M 
value 62.4 vs 9.6, respectively. There was significant correlations between M value and HbA1c (p<0.01), and between average 
glucose and HbA1c (p<0.01).Triglyceride value was decreased for 12 days of LCD from 103 to 79 mg/dL.  
 
Discussion and Conclusion: The results suggested that LCD showed positive effects for improving glucose variability and lipid 
metabolism. Furthermore, these findings would become fundamental and reference data for the future research development in 
this field. 
 
Keywords: Glucose variability; Morbus value (M value); Low carbohydrate diet (LCD); Triglyceride (TG); Type 2 diabetes mellitus 
(T2DM) 
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1. Abbreviation  
 LCD: Low Carbohydrate Diet 
 T2DM: Type 2 diabetes mellitus  
 IRI: Immunoreactive insulin 
 M value: Morbus value  
 HOMA-R: Homeostasis model assessment of insulin resistance  
 HOMA-β: Homeostasis model assessment of β cell function 
 
2. Introduction 
Diabetes has been a crucial problem for years in developed countries and also developing countries. It is not only medical 
matter, but also social and economic matters [1]. As there have been various problems of diabetes, adequate treatment and 
management would be necessary in diabetic cure and care. Especially, diabetic nutritional therapy would be the important 
and fundamental in the clinical practice. 
 
From the basic medical point of view, the main cause of diabetic complications are from persisting elevated blood glucose 
and fluctuation of glucose [2,3]. As to microvascular complications, there seemed to be several probable mechanisms 
influencing the biochemical changes. They may include some possibility, such as the formation of advanced glycation end 
products (AGEs), increased flux of glucose and other sugars through the polyol pathway, activation of protein kinase C 
(PKC) isoforms and increased flux through the hexosamine pathyway [4,5].  
 
From the clinical practice, management for diabetes has been on discussion concerning diagnosis and treatment. Recently, 
there has been controversy on discussion concerning the recommended HbA1c in American College of Physicians (ACP), 
American Diabetes Association (ADA) and International Diabetes Federation (IDF) [6-8]. Thus, applicable control of 
diabetic variability has been important to be argued [9].  
 
Adequate nutritional therapy has been the fundamental treatment for diabetes and Metabolic syndrome (Met-S). The method 
of Calorie Restriction (CR) has been the main principle for diet therapy widely, but in 1990’ Bernstein et al. started to apply 
Low Carbohydrate Diet (LCD) [10]. The efficacy of LCD for weight reduction and glucose lowering has been reported and 
recognized so far. After that, Shai et al. showed the data of the comparison of the efficacy of LCD, Mediterranean, Low-Fat 
Diet [11,12]. Various discussion between CR and LCD has been continued for long years [13,14]. 
 
On the other hand, authors and colleagues in Japan have introduced and developed LCD in Japan for long years [15]. We 
have continued and developed LCD movement in various axes, including educational seminars, medical journals and books 
and presenting in medical society [16].  
 
We have also reported the pathophysiological role of Ketone Bodies (KB) in the circumstances of fetus, placenta, newborn 
and mother [17]. In addition, we have developed the prevalence of LCD by continuing the activity of Japan LCD promotion 
association [18]. We have recommended simple way of LCD in 3 types, which are super LCD, moderate LCD and petite 
LCD meals [19].  
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In current investigation, we compared the glucose variability on CR diet and LCD, and calculated the difference of average 
blood glucose and Morbus (M) value.  
 
Moreover, we study the detail comparison and correlations among several biomarkers, such as HbA1c, glucose, lipid profile, 
homeostasis model assessment of insulin resistance (HOMA-R) and homeostasis model assessment of β cell function 
(HOMA-β).  
 
3. Subjects and Methods 
Current study enrolled 81 female patients with Type 2 Diabetes Mellitus (T2DM). Subjects were diagnosed as diabetes 
mellitus, and admitted to the hospital. The purpose was to evaluate diabetic status in detail, to provide two types of diabetic 
meal which are calorie restriction (CR) and low carbohydrate diet (LCD), and to make them to understand the importance of 
nutritional therapy for diabetics.  
 
Regarding the methods, we have continued our diabetic formula protocol of treatment and research program. We proceeded a 
certain criteria in the following: 
 The subjects in this study were diagnosed as T2DM. Other types of diabetes such as type 1 diabetes mellitus 
(T1DM) or specific rare type of diabetics were excluded. The subjects were not given medicine which may 
influence glucose metabolism or glucose variability.  
 Diabetic patients were admitted for 2 weeks for exam and treatment in the hospital. On the next morning of the 
admission day, which is day 2 morning, we ordered basal blood test after overnight fast. They included several basal 
biomarkers such as complete blood count, liver, renal lipids and so on. As to specific exam items for diabetes, blood 
values of HbA1c, glucose, IRI, C-peptide, HOMA-R, HOMA-β, M value were obtained for the study. 
 Our protocol test has nutritional therapy in the following. Subjects have on CR meal on day 1 and day 2, in which 
CR contains PFC ratio is 15: 25: 60 with 1400 kcal/day. This standard meal is from the proposal of Japan Diabetes 
Association (JDA) [20].  
 Patients were given LCD meal from day 3 to 14 with super LCD. The content has 12% of carbohydrate with 1400 
kcal/day. This is called super LCD, and this has been popular and used for LCD promotion activity in Japan. We 
have other two formula, which are standard LCD with carbohydrate 26% and petite LCD with carbohydrate 40%. 
These 3 types of LCD have been educated and known to people so far. In current study, all subjects took only super 
LCD with 12% of carbohydrate.  
 Biomarkers related to diabetes were measured in day 2, day 4 and day 14. Blood samples in both days were drawn in 
the morning after overnight fasting. Both data and several correlations were compared and investigated. The reason 
of exam on day 2 and day 4 is the comparison of glucose variability after 2 days of LCD meal. On contrast, the 
reason of exam on day 2 and day 14 is the comparison with lipid metabolism after 12 days of LCD meal.  
 
3.1 Glucose variability a day 
For the study of glucose variability, we measured the daily profile of blood glucose on day 2 and day 4. In each day, blood 
glucose values were checked 7 times a day, which were 08, 10, 12, 14, 17, 19 and 22h. After measuring the glucose data, 
average blood glucose per day and also the level of M value were calculated using the formula equation [21,22].  
www.yumedtext.com | September-2018 
4 
3.2 M value  
M value has been one of the useful biomarker for glucose variability. It means two crucial aspects for glucose variability. 
One is the level of the average blood glucose in a day, and another is the degree of swinging glucose in a day, which is called 
as the mean amplitude of glycemic excursions (MAGE) [21-23].  
 
Consequently, M value is expressed as a numerical value including the meaning for two important markers. They are the 
degree of elevated blood glucose and increased fluctuation of blood glucose. According to the mathematical equation, M 
value can be easily calculated as the method of logarithmic transformation. It can be said that the significance of M value 
expresses the glucose deviation from the ideal glucose variability [22-24]. 
 




 : M value 




. In the next step, M
W
 expresses (maximum blood glucose − minimum glucose)/20. In third 
step, M
BS
 is the mean of MBSBS. When these are summarized, MBSBS has been the individual M-value for each blood 




Concerning the level of M value, clinical judgement for glucose variability can be used for general. There is standard normal 
range of M value as follows: less than 180 is normal, from 180 to 320 would be borderline, more than 320 would be 
abnormal. 
 
3.3 Statistical analysis 
Concerning this study, data were expressed by the mean and standard deviation. Furthermore, several data were also 
expressed as the median and the quartile of 25% and 75%. In the case of the comparison among some groups, we used the 
method of boxplot. It can express 5 data simultaneously, which are the median and the quartile of 25% / 75 % from the box, 
maximum and minimum from the upper and lower lines. Regarding the correlation with biomarkers, we used the Spearman 
test for the correlation coefficients. Moreover, the computerized standard statistical tool has been used for analytical 
evaluation [25]. 
 
3.4 Ethical Considerations 
Current investigation was basically conducted in compliance with the ethical principles based upon the Declaration of 
Helsinki. Furthermore, additional commentary was performed in the Ethical Guidelines for Medical Research in Humans and 
in accordance with the Good Clinical Practice (GCP), which were with the ongoing consideration to the protection of 
subjects’ human rights. In addition, adequate guideline was used, which was the “Ethical Guidelines for Epidemiology 
Research” by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labor and 
Welfare. The author and colleague researchers have had an ethical committee. In the case of discussion, medical doctor, 
nurse, pharmacist, nutritionist and other experts in the legal specialty attended. Concerning this study, we have discussed and 
confirmed that this study would be valid and agreed. In addition, the informed consents and written paper agreements have 
been obtained from the subjects. This study has been registered by National University Hospital Council of Japan (ID: 
#R000031211). 
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       4. Results 
      4.1 Basal data 
In this study, 81 female patients with T2DM were enrolled and their basal data were summarized in TABLE 1. Average age 
was 62.4 years old with 64 years old in median. Median value of HbA1c, fasting blood glucose and IRI was 7.2%, 147 
mg/dL and 6.8 μU/mL, respectively. Median value of HOMA-R and HOMA-β was 2.5 and 28.7, respectively. 
 
TABLE 1. Subjects and basal data. 
        Mean ± SD Median [25%-75%] 
  Subjects 
 
age (years old) 62.4 ±11.8 64[55-70] 
  
  
number (M/F) 81 (0/81) 81(0/81) 
  
  
No. in group (1, 2, 3, 4) 20, 20, 20, 21 20, 20, 20, 21 
  Glucose profile 
 





155 ± 46.2 147[120-180] 
  
  




HOMA-R 2.9 ± 1.9 2.5[1.5-3.9] 
  
  
HOMA-β 37.9 ± 34.3 28.7[16.6-48.0] 
 
      4.2 Biomarkers in day 2 vs day 4 
In response to the LCD meal, the values of biomarkers between day 2 and day 4 were compared in TABLE 2. Decreased 
median values from day 2 vs day 4 were observed in average blood glucose, M value and urinary C-peptide 
immunoreactivity (CPR), which were 173 vs 130 mg/dL, 62.4 vs 9.6, 54.0 vs 44.0 mg/dL, respectively. 
 
TABLE 2. Comparison of the data on day 2 and day 4. 
   
Mean ± SD median [25% - 75%] 
Average 
glucose  
Day 2 (mg/dL) 187 ± 65.1 173[135-221] 
  
Day 4 (mg/dL) 140 ± 40.5 130[108-159] 
M value 
 
Day 2 146 ± 198 62.4[17.8-179] 
  
Day 4 30.6 ± 51.0 9.6[4.9-24.6] 
Urine C-
Peptide  
Day 2 (mg/day) 66.3 ± 37.9 54.0[41.0-78.6] 
  
Day 4 (mg/day) 52.3 ± 29.3 44.0[33.4-62.1] 
  
     4.3 Lipid profile on day 2 vs day 14 
Lipid profile was studied between day 2 and day 14 in response to LCD for 12 days. Both blood sampling were performed 
after overnight fasting without influence of meal (TABLE 3). The median values of day 2 vs day 14 were measured in 
triglyceride, HDL-C and LDL-C, which were 103 vs 79 mg/dL, 62 vs 56 mg/dL, and 131 vs 139 mg/dL, respectively. 
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TABLE 3. Lipid metabolism between day 2 and day 14. 
      Mean ± SD Median [25% - 5%] 
Triglyceride 
(mg/dL)  
Day  2 (mg/dL) 120 ± 61.3 103[78.0-151] 
 
  Day 14 (mg/dL) 82.8 ± 29.6 79.0[60.3-94.8] 
HDL-C (mg/dL) 
 
Day  2 (mg/dL) 63.8 ± 15.2 62.0[52.8-69.5] 
 
  Day 14 (mg/dL) 58.6 ± 14.6 56.0[48.0-65.3] 
LDL-C (mg/dL) 
 
Day  2 (mg/dL) 134 ± 39.6 131[107-158] 
 
  Day 14 (mg/dL) 147 ± 41.4 139[122-171] 
 
    4.4 Biomarkers on day 2 
The values of HbA1c and average glucose on day 2 in each group were shown in FIG. 1. The median data in 4 groups were 
6.0, 7.0, 7.9, 9.4% and 123, 155,193, 264 mg/dL, respectively. 
  
                
1a: HbA1c                                                                                       1b: Average Glucose 
 
FIG. 1. HbA1c and average glucose on day 2 in each group. 
 
Similarly, the data of HOMA-R and HOMA-β were 2.1, 2.5, 2.2, 2.6 and 48.5, 39.1, 21.3, 16.3, respectively (FIG. 2). The 
former did not show the difference in 4 groups, but the latter showed the decreasing data from group 1 to 4. 
    
         
                     2a: HOMA-R                                                                                2b: HOMA-β 
 
 
FIG. 2. HOMA-R and HOMA-β on day 2 in each group. 
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The correlations of the data in day 2 among biomarkers were investigated. There was significant correlations between M 
value and HbA1c (p<0.01), and between average glucose and HbA1c (p<0.01) (FIG. 3).  
 
 
                       
FIG. 3. Correlation among HbA1c, average glucose and M value on day 2. 
 
  4.5 Comparison on day 2 vs day 4  
The values of average glucose on day 2 vs day 4 were compared in 4 groups (FIG. 4). The median value in each group was 
122 vs 99 mg/dL, 155 vs 123 mg/dL, 193 vs 136 mg/dL, 264 vs 190 mg/dL, respectively. There were remarkable decrease 




FIG. 4. Changes in average glucose from day 2 to 4 in each group. 
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The levels of M value on day 2 vs day 4 were compared in 4 groups (FIG. 5). The median value in each group was 7.5 vs 8.2, 
37.2 vs 6.2, 111 vs 9.7, 330 vs 67, respectively. In group 1, the data of M value was not changed. In group 2,3,4, there were 
remarkable decrease of M value during 2 days.  
                        
 
 
FIG. 5. Changes in M value from day 2 to 4 in each group. 
 
      4.6 Correlation between on day 2 and day 4  
The values of average glucose and M value were compared between on day 2 and day 4 (FIG.6). There were significant 




FIG. 6. Correlations of glucose and M value between day 2 and 4. 
 
     4.7 Lipid profile on day 2 and day 14 
The levels of triglyceride on day 2 vs day 14 were compared in 4 groups (FIG.7). The median value in each group was 116 vs 
74 mg/dL, 109 vs 82 mg/dL, 89 vs 75 mg/dL, 89 vs 79 mg/dL, respectively. There were decrease in all groups. 




                                      7a: Group 1 and 2                                                    7b: Group 3 and 4 
 
FIG. 7. Changes in Triglyceride from day 2 to 14 in each group. 
 
      5.    Discussion 
In our medical practice, we have provided treatment on many cases of metabolic syndrome, obesity and diabetic patients. At 
the same time, we have continued clinical research, and spread the information and tips of how to continue LCD with three 
types of LCD meals. Simple and recommended methods are super LCD, standard LCD and petite LCD with the carbohydrate 
12%, 26% and 40%, respectively [18,19]. As a result, medical and social understanding for LCD has been found in recent 
years [14,26].  
  
In this study, we studied the detail investigation for glycemic variability on 81 female patients with T2DM. In the research 
design, limitation of female was due to the fact that diabetic research usually has heterogeneous factors, then trying to have 
common factors in the background. In addition, they were categorized into 4 groups according to the level of M value. It is an 
index of hyperglycemia and blood sugar fluctuation range, which seemed to be useful for the analysis for the data. The results 
of this study are shown in Tables and Figures, and are discussed in this order.  
 
The background of the subject and obtained data were shown in two ways. In addition to the conventional description, 
average ± standard deviation (SD), the median and quartile 25% and 75% are also calculated and shown by box plot (box-
and-whisker plot) method [27]. Although it is rather difficult to grasp the whole situation with the former data only, the latter 
method can show the general condition. The reason is that the box range represents the width of 50% of the subjects in the 
group. In particular, since the fluctuation range of the M value is large, it is reasonable to judge by the median value rather 
than the average value. 
 
Three biomarkers which are mean glucose, M value and urinary CPR decreased remarkably by LCD diet only for 2 days, 
suggesting the clinical effect in short period [28]. Among the, M value markedly decreased in particular. Indicating both 
mean blood sugar and fluctuation range, M value seems to be useful for grasping blood glucose fluctuation [16]. 
Furthermore, in the case of follow-up study and observations, variations in M value can indicate more significant than 
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fluctuations in blood glucose [29,30]. Consequently, the detail differences can be captured by M value, associated with the 
usefulness for clinical research in the future.  
 
We divided into 4 groups according to the level of M value. As to HbA1c and mean blood glucose, they showed less overlap 
area and rather well-divided distribution, suggesting that the grouping would be appropriate and useful. In the distribution of 
4 groups, the overlap was broad in HOMA-R and the distribution was rather divided in HOMA-β. The former shows insulin 
resistance and the latter shows the insulin secretion ability from β cells of the pancreas [31]. From the above, it seems that 
relationship with insulin secretion would be related to the higher blood glucose and wider fluctuation of glucose. 
 
Significant correlation was found among the biomarkers of HbA1c, mean blood glucose and M value. The correlation 
coefficients were roughly the same as r
2
 = 0.43 and r
2
 = 0.5. The correlation coefficient between the average blood glucose 
and the M value is very high, since the M value is calculated from the average blood sugar value [22,23]. HbA1c expresses 
the average glucose variability over the past month, while mean blood glucose directly represents the blood glucose 
fluctuation of the day studied [24,25]. Various clinical studies of diabetes seem to be possible by utilizing these three 
biomarkers. 
 
In the study of 4 groups, the average blood glucose and M value generally dropped between day 2 and day 4. Among them, 
the M value was almost the same in group 1 of the M value. The reason is based on the calculation formula of M value [22-
25]. Since the standard level of blood glucose is 120 mg / dL, the M value is the smallest when the glucose is around 120 
mg/dL [32,33]. If the average glucose changes from 120 mg/dL to 100 mg/dL, M value changes from the minimum to higher 
value. 
 
It was observed that M value of group 2 and 3 decreased to less than 10 on day 4. This is from the fact that means blood 
glucose was decreased to 123mg/dL and 136 mg/dL, respectively. When observing the boxplot of mean blood glucose and M 
value in group 4, it is clearly understood that the change in blood glucose was improved in 50% of the subjects indicated by 
the box area. 
 
From day 2 to day 4, average blood glucose and M value decreased in the same way. Observing the correlation coefficient, it 
is very high with R
2
 = 0.88, 0.84, respectively. In other words, it can be said that the reduction rate of corresponding data is 
about the same level as a whole [14,34]. The regression curve of blood glucose is y = 0.58 x +30.7, indicating the sufficient 
effect of LCD only for 2 days [14,35]. When we enter x = 200 into the equation, the calculation shows that y= 147. As to M 
value, the regression curve is y = 0.24 x -3.7. Since the slope is small which is 0.24, the M value becomes much lower in 
comparison with the data of day 2 and day 4. 
 
For the lipid profile, the value of TG was sufficiently reduced for 12 days of LCD. Our results were consistent with previous 
reports [13,26]. On the other hand, the trend of HDL-C rise and LDL-C declining tendency was not clear. According to the 
previous report [13], TG will decline in a short period of time by LCD, and after several months HDL-C will show a slight 
upward trend. On contrast, LDL-C has been not variable, which are rising, constant or decreasing [26]. Although it was a 
short period in this study, TG descends sufficiently, indicating clinical effect of LCD. As mentioned above, we described 
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various speculations from the results of. However, there is limit in this research. Although the effects of the LCD were 
observed under the current conditions, the effect will be different in the actual life of each patient. Then, further evaluation 
under various situations would be necessary. Furthermore, three types of LCDs proposed by us would be useful for various 
diabetic patients, which are super, standard, petite LCD meal in their daily lives.  
 
5. Conclusion 
In summary, we investigated 81 female patients with T2DM. Diabetes related biomarkers including HbA1c, glucose, IRI, 
HOMA-R, HOMA-β were measured and correlations were investigated. In response to LCD for only 2 days, average glucose 
level, M value and urinary C-peptide excretion were remarkably decreased. Triglyceride value was decreased for LCD in 12 
days. These results suggest that LCD would be clinically effective for T2DM and these findings would become reference and 
basal data in this research, leading to future research development.  
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